OKYO Pharma's chairman Gabriele Cerrone speaks with Proactive following news of a successful pre-IND meeting with the U.S. Food and Drug Administration regarding the development of its OK-101 drug to treat dry eye disease. He says they're now planning to take OK-101 direct into Phase 2 clinical trials and should the study meet its pre-specified primary endpoints it would be an important step in reducing the timeline to a new drug application filing with the FDA.
OKYO Pharma to take dry eye disease drug direct into Phase 2 clinical trials
